GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of “Hold” from Analysts

GoodRx Holdings, Inc. (NASDAQ:GDRX) has received a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation, six have given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $4.7292.

Several equities analysts have weighed in on the stock. TD Cowen lowered their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. Barclays initiated coverage on GoodRx in a report on Monday, December 8th. They set an “underweight” rating and a $3.00 price target on the stock. Citigroup reduced their price objective on GoodRx from $5.00 to $4.50 and set a “buy” rating for the company in a research note on Friday, January 9th. Morgan Stanley decreased their price objective on GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Finally, Mizuho dropped their target price on GoodRx from $5.00 to $4.00 and set a “neutral” rating on the stock in a report on Thursday, November 6th.

GoodRx Trading Down 5.4%

Shares of GDRX opened at $2.27 on Monday. The business’s 50-day moving average price is $2.71 and its 200 day moving average price is $3.58. The company has a current ratio of 3.11, a quick ratio of 3.11 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $770.51 million, a P/E ratio of 25.22, a P/E/G ratio of 0.91 and a beta of 1.45. GoodRx has a 1-year low of $2.24 and a 1-year high of $5.81.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). The firm had revenue of $196.03 million for the quarter, compared to analysts’ expectations of $195.17 million. GoodRx had a net margin of 3.97% and a return on equity of 9.73%. GoodRx’s quarterly revenue was up .4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.08 earnings per share. Analysts expect that GoodRx will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On GoodRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quarry LP purchased a new position in shares of GoodRx during the 3rd quarter valued at $33,000. Boothbay Fund Management LLC acquired a new stake in GoodRx during the third quarter valued at $43,000. Shay Capital LLC purchased a new position in GoodRx in the third quarter valued at about $47,000. Cetera Investment Advisers purchased a new position in GoodRx in the second quarter valued at about $50,000. Finally, Walled Lake Planning & Wealth Management LLC acquired a new position in GoodRx in the 2nd quarter worth about $55,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.